{"id":4589,"date":"2026-02-28T10:11:25","date_gmt":"2026-02-28T07:11:25","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=4589"},"modified":"2026-02-28T10:41:37","modified_gmt":"2026-02-28T07:41:37","slug":"bir-gun-degil-her-gun-nadirin-sesi-olmayi-surdurecegiz-copy","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=4589","title":{"rendered":"Bir G\u00fcn De\u011fil, Her G\u00fcn \u2018Nadir\u2019in Sesi Olmay\u0131 S\u00fcrd\u00fcrece\u011fiz"},"content":{"rendered":"\n<p><strong>T\u00fcrk ila\u00e7 sekt\u00f6r\u00fcn\u00fcn lider \u015firketi Abdi \u0130brahim, nadir hastal\u0131klar alan\u0131n\u0131 yaln\u0131zca bir terap\u00f6tik ba\u015fl\u0131k olarak de\u011fil, uzun soluklu bir sorumluluk alan\u0131 olarak konumland\u0131r\u0131yor. Bilimsel ilerlemelerin h\u0131z kazand\u0131\u011f\u0131, erken tan\u0131 ve yenilik\u00e7i tedavi se\u00e7eneklerinin giderek daha fazla \u00f6nem kazand\u0131\u011f\u0131 bu alanda \u015firket; hasta odakl\u0131 yakla\u015f\u0131m\u0131, g\u00fc\u00e7l\u00fc Ar-Ge altyap\u0131s\u0131 ve uluslararas\u0131 i\u015f birlikleriyle s\u00fcrd\u00fcr\u00fclebilir bir de\u011fer yaratmay\u0131 hedefliyor. Re\u00e7eteli \u00dcr\u00fcnler Pazarlama ve Sat\u0131\u015f Grup Ba\u015fkan\u0131 Figen Bilgen ile Nadir Hastal\u0131klar B\u00f6l\u00fcm Direkt\u00f6r\u00fc Cevdet Cenk \u00c7etin, nadir hastal\u0131klarda eri\u015fimden fark\u0131ndal\u0131\u011fa, tan\u0131 s\u00fcre\u00e7lerinden gelecek vizyonuna uzanan kapsaml\u0131 bir perspektifi payla\u015f\u0131yor.<\/strong><\/p>\n\n\n\n<p><strong>Figen Bilgen, sizi ve Abdi \u0130brahim\u2019i tan\u0131yabilir miyiz?<\/strong><\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignleft size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"695\" height=\"1024\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/figen-bilgen-copy1-695x1024.jpg\" alt=\"\" class=\"wp-image-4568\" style=\"width:189px;height:auto\" srcset=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/figen-bilgen-copy1-695x1024.jpg 695w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/figen-bilgen-copy1-204x300.jpg 204w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/figen-bilgen-copy1-768x1131.jpg 768w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/figen-bilgen-copy1-1043x1536.jpg 1043w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/figen-bilgen-copy1.jpg 1120w\" sizes=\"(max-width: 695px) 100vw, 695px\" \/><\/figure><\/div>\n\n\n<p>ODT\u00dc \u0130\u015fletme B\u00f6l\u00fcm\u00fc mezunuyum. \u0130\u015f hayat\u0131na bankac\u0131l\u0131k sekt\u00f6r\u00fcnde, pazarlama alan\u0131nda ba\u015flad\u0131m. K\u0131sa s\u00fcre sonra ila\u00e7 sekt\u00f6r\u00fcne ge\u00e7i\u015f yapt\u0131m ve 35 y\u0131ll\u0131k profesyonel yolculu\u011fumun oda\u011f\u0131n\u0131 yakla\u015f\u0131k 33 y\u0131ld\u0131r ila\u00e7 sekt\u00f6r\u00fc olu\u015fturuyor. Abdi \u0130brahim\u2019e ise 2017 y\u0131l\u0131nda Pazarlama ve Sat\u0131\u015f Direkt\u00f6r\u00fc olarak kat\u0131ld\u0131m. 2021\u2019de Genel Tedaviler Grup Direkt\u00f6r\u00fc g\u00f6revini \u00fcstlendim. Ekim 2023\u2019ten bu yana da Re\u00e7eteli \u00dcr\u00fcnler Pazarlama ve Sat\u0131\u015f Grup Ba\u015fkan\u0131 olarak \u00e7al\u0131\u015f\u0131yorum.<\/p>\n\n\n\n<p>T\u00fcrk ila\u00e7 sekt\u00f6r\u00fcn\u00fcn lider \u015firketi Abdi \u0130brahim\u2019de bu g\u00f6revi \u00fcstlenmek, k\u00f6kl\u00fc bir miras\u0131 gelece\u011fe ta\u015f\u0131ma sorumlulu\u011funu beraberinde getiriyor. Kurucumuz Eczac\u0131 Abdi \u0130brahim Bey\u2019in 1912 y\u0131l\u0131nda \u0130stanbul K\u00fc\u00e7\u00fckmustafapa\u015fa\u2019daki bir eczanede ba\u015flatt\u0131\u011f\u0131 iyile\u015ftirme yolculu\u011fu, bug\u00fcn 5.800 \u00e7al\u0131\u015fan\u0131, 250 marka ve 500\u2019\u00fcn \u00fczerinde \u00fcr\u00fcn\u00fcyle T\u00fcrkiye\u2019nin en b\u00fcy\u00fck ila\u00e7 \u015firketi unvan\u0131n\u0131 ta\u015f\u0131yan g\u00fc\u00e7l\u00fc bir organizasyona d\u00f6n\u00fc\u015fm\u00fc\u015f durumda.<\/p>\n\n\n\n<p>Bug\u00fcn, 20 \u00fclkede kendi organizasyonel yap\u0131m\u0131zla y\u00fcr\u00fctt\u00fc\u011f\u00fcm\u00fcz faaliyetler, 70\u2019ten fazla \u00fclkeye ger\u00e7ekle\u015ftirdi\u011fimiz ihracat ve T\u00fcrkiye\u2019nin en y\u00fcksek istihdam sa\u011flayan ila\u00e7 \u015firketi olmam\u0131z sayesinde, yaln\u0131zca ulusal de\u011fil, ayn\u0131 zamanda uluslararas\u0131 bir sa\u011fl\u0131k oyuncusuna da d\u00f6n\u00fc\u015fm\u00fc\u015f durumday\u0131z. Bu ba\u015far\u0131y\u0131; bilime ve teknolojiye s\u00fcrekli yat\u0131r\u0131m yapan, yenilik\u00e7ili\u011fi ve insan odakl\u0131l\u0131\u011f\u0131 \u00f6nceliklendiren de\u011fer temelli bir \u015firket k\u00fclt\u00fcr\u00fcyle s\u00fcrd\u00fcr\u00fcyoruz.<\/p>\n\n\n\n<p><strong>Abdi \u0130brahim olarak nadir hastal\u0131klar alan\u0131n\u0131 stratejik \u00f6ncelik haline getirme karar\u0131n\u0131z nas\u0131l \u015fekillendi?<\/strong><\/p>\n\n\n\n<p><strong>Figen Bilgen:<\/strong> Nadir hastal\u0131klar alan\u0131 hem bilimsel hem de toplumsal a\u00e7\u0131dan sa\u011fl\u0131k sistemlerinin en hassas ve en fazla odak gerektiren alanlar\u0131ndan biri. D\u00fcnya genelinde 300 milyondan fazla, \u00fclkemizde ise milyonlarca insan\u0131 etkileyen bu hastal\u0131klar&nbsp; \u201cnadir\u201d olarak tan\u0131mlansa da hasta ve aileler i\u00e7in son derece derin ve uzun soluklu bir m\u00fccadele anlam\u0131na geliyor.<\/p>\n\n\n\n<p>Son y\u0131llarda genetik tan\u0131 y\u00f6ntemlerindeki ilerlemeler, biyoteknolojideki geli\u015fmeler ve artan fark\u0131ndal\u0131k sayesinde bu alanda \u00f6nemli bir ivme yakaland\u0131. Ancak h\u00e2l\u00e2 tan\u0131 s\u00fcre\u00e7lerinin uzunlu\u011fu, s\u0131n\u0131rl\u0131 tedavi se\u00e7enekleri ve eri\u015fim zorluklar\u0131, nadir hastal\u0131klar\u0131 stratejik ve s\u00fcrd\u00fcr\u00fclebilir bir yakla\u015f\u0131mla ele almay\u0131 zorunlu k\u0131l\u0131yor.<\/p>\n\n\n\n<p>Abdi \u0130brahim olarak biz, sa\u011fl\u0131k alan\u0131nda de\u011fer yaratmay\u0131 yaln\u0131zca y\u00fcksek hacimli terap\u00f6tik alanlarla s\u0131n\u0131rl\u0131 g\u00f6rm\u00fcyoruz. Kurulu\u015fumuzdan bu yana benimsedi\u011fimiz vizyon; kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131n oldu\u011fu alanlarda sorumluluk almak ve bilimin sundu\u011fu imk\u00e2nlar\u0131 hasta yarar\u0131na d\u00f6n\u00fc\u015ft\u00fcrmek. Nadir hastal\u0131klar da tam olarak bu yakla\u015f\u0131m\u0131n kesi\u015fim noktas\u0131nda yer al\u0131yor.<\/p>\n\n\n\n<p>2002 y\u0131l\u0131ndan bu yana edindi\u011fimiz uluslararas\u0131 i\u015f birlikleri deneyimi, g\u00fc\u00e7l\u00fc Ar-Ge ve biyoteknoloji oda\u011f\u0131m\u0131z ile karma\u015f\u0131k ve uzmanl\u0131k gerektiren alanlara yat\u0131r\u0131m yapabilecek bir yetkinlik seviyesine ula\u015ft\u0131k. Nadir hastal\u0131klar alan\u0131n\u0131 stratejik \u00f6ncelik haline getirme karar\u0131m\u0131z; bilimsel kapasitemizin, global ortakl\u0131klar\u0131m\u0131z\u0131n ve hasta odakl\u0131 yakla\u015f\u0131m\u0131m\u0131z\u0131n do\u011fal bir sonucu olarak \u015fekillendi.<\/p>\n\n\n\n<p>Bu alandaki hedefimiz yaln\u0131zca \u00fcr\u00fcn portf\u00f6y\u00fc geni\u015fletmek de\u011fil; tan\u0131dan tedaviye uzanan yolculukta hastalara, hekimlere ve sa\u011fl\u0131k ekosistemine uzun vadeli, s\u00fcrd\u00fcr\u00fclebilir de\u011fer sunmak. \u00c7\u00fcnk\u00fc biz, ger\u00e7ek liderli\u011fin en zor alanlarda sorumluluk almaktan ge\u00e7ti\u011fine inan\u0131yoruz.<\/p>\n\n\n\n<p><strong>T\u00fcrkiye\u2019de geri \u00f6deme sistemleri ve tedaviye eri\u015fim konusunu nadir hastal\u0131klar \u00f6zelinde nas\u0131l de\u011ferlendiriyorsunuz?<\/strong><\/p>\n\n\n\n<p><strong>Figen Bilgen:<\/strong> Geri \u00f6deme sistemleri ve tedaviye eri\u015fim, nadir hastal\u0131klar alan\u0131nda t\u00fcm d\u00fcnyada en hassas ve en karma\u015f\u0131k ba\u015fl\u0131klardan biri, \u00e7\u00fcnk\u00fc bu alanda hasta say\u0131s\u0131 s\u0131n\u0131rl\u0131 olsa da tedavi maliyetleri genellikle y\u00fcksek ve uzun vadeli bir planlama gerektiriyor. Bu nedenle s\u00fcrd\u00fcr\u00fclebilir, \u00f6ng\u00f6r\u00fclebilir ve hasta odakl\u0131 bir geri \u00f6deme modeli kritik \u00f6nem ta\u015f\u0131yor.<\/p>\n\n\n\n<p>T\u00fcrkiye, son y\u0131llarda hem erken tan\u0131 mekanizmalar\u0131 hem de geri \u00f6deme s\u00fcre\u00e7leri a\u00e7\u0131s\u0131ndan \u00f6nemli ad\u0131mlar att\u0131. Yenido\u011fan tarama programlar\u0131n\u0131n geni\u015fletilmesi ve evlilik \u00f6ncesi tarama uygulamalar\u0131, baz\u0131 nadir hastal\u0131klar\u0131n daha erken evrede tespit edilmesini m\u00fcmk\u00fcn k\u0131l\u0131yor. Erken tan\u0131, yaln\u0131zca klinik sonu\u00e7lar\u0131 iyile\u015ftirmekle kalm\u0131yor; ayn\u0131 zamanda sa\u011fl\u0131k sisteminin kaynaklar\u0131n\u0131 daha etkin kullanmas\u0131na da katk\u0131 sa\u011fl\u0131yor.<\/p>\n\n\n\n<p>Geri \u00f6deme taraf\u0131nda ise, sa\u011fl\u0131k otoriteleri ile ila\u00e7 end\u00fcstrisi aras\u0131nda kurulan yap\u0131c\u0131 diyalog ve i\u015f birli\u011fi, eri\u015fimin g\u00fc\u00e7lenmesinde belirleyici rol oynuyor. T\u00fcrkiye\u2019de son d\u00f6nemde hayata ge\u00e7irilen iyile\u015ftirmeler sayesinde bir\u00e7ok nadir hastal\u0131k tedavisi daha sistematik ve s\u00fcrd\u00fcr\u00fclebilir bi\u00e7imde hastalara ula\u015ft\u0131r\u0131labiliyor. Tan\u0131 s\u00fcreci \u00e7o\u011fu zaman y\u0131llar s\u00fcrebilen bu hastal\u0131klar i\u00e7in, uygun tedaviye zaman\u0131nda eri\u015fim hayati bir e\u015fik anlam\u0131na geliyor.<\/p>\n\n\n\n<p>Biz de sa\u011fl\u0131k ekosistemindeki t\u00fcm payda\u015flar\u0131m\u0131zla birlikte, eri\u015fimi art\u0131ran, s\u00fcre\u00e7leri h\u0131zland\u0131ran ve hasta odakl\u0131 \u00e7\u00f6z\u00fcmleri yayg\u0131nla\u015ft\u0131ran yakla\u015f\u0131mlar\u0131n destek\u00e7isi olmaya devam edece\u011fiz.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-web-4-1024x683.jpg\" alt=\"\" class=\"wp-image-4585\" style=\"width:383px;height:auto\" srcset=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-web-4-1024x683.jpg 1024w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-web-4-300x200.jpg 300w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-web-4-768x512.jpg 768w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-web-4-1536x1024.jpg 1536w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-web-4-2048x1366.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/div>\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Toplumda nadir hastal\u0131klara y\u00f6nelik fark\u0131ndal\u0131\u011f\u0131n artmas\u0131 i\u00e7in ila\u00e7 \u015firketlerine ve di\u011fer payda\u015flara d\u00fc\u015fen sorumluluklar sizce nelerdir? Abdi \u0130brahim olarak siz neler yap\u0131yorsunuz?<\/strong><\/p>\n\n\n\n<p><strong>Figen Bilgen:<\/strong> Nadir hastal\u0131klar, t\u00fcm payda\u015flar\u0131n e\u015fg\u00fcd\u00fcm i\u00e7inde hareket etmesini gerektiren uzun ve \u00e7ok katmanl\u0131 bir alan. Hastal\u0131\u011f\u0131n bilinirli\u011finin artmas\u0131, hastalar\u0131n zaman\u0131nda tan\u0131 almas\u0131, uygun tedaviye ba\u015flamas\u0131 ve tedavinin s\u00fcrd\u00fcr\u00fclebilirli\u011fi bu s\u00fcrecin temel a\u015famalar\u0131n\u0131 olu\u015fturuyor. Bu yolculukta her payda\u015f\u0131n kendisine \u00f6zel \u00f6nemli sorumluluklar\u0131 oldu\u011funa inan\u0131yoruz. Biz de nadir hastal\u0131klar alan\u0131nda hem fark\u0131ndal\u0131\u011f\u0131n artmas\u0131na hem de hastalar\u0131n tedavi s\u00fcre\u00e7lerine de\u011fer katacak \u00e7\u00f6z\u00fcmler geli\u015ftirmeye odaklan\u0131yoruz.<\/p>\n\n\n\n<p>Abdi \u0130brahim olarak, bu zorlu yolculu\u011fun sadece bir izleyicisi de\u011fil, \u00e7\u00f6z\u00fcm\u00fcn en g\u00fc\u00e7l\u00fc orta\u011f\u0131y\u0131z. T\u0131bb\u0131n en g\u00fc\u00e7 alanlar\u0131ndan biri olan bu sahada, iyile\u015ftirme yolculu\u011funa olan tutkulu ba\u011fl\u0131l\u0131\u011f\u0131m\u0131zla bilimin s\u0131n\u0131rlar\u0131n\u0131 zorluyor; her bir hastan\u0131n nefesine dokunabilmek i\u00e7in aral\u0131ks\u0131z \u00e7al\u0131\u015f\u0131yoruz.<\/p>\n\n\n\n<p>Biz, fark\u0131ndal\u0131\u011f\u0131n yaln\u0131zca belirli g\u00fcnlerde yap\u0131lan ileti\u015fim \u00e7al\u0131\u015fmalar\u0131yla s\u0131n\u0131rl\u0131 kalmamas\u0131 gerekti\u011fine inan\u0131yoruz. Bu nedenle sa\u011fl\u0131k profesyonellerine y\u00f6nelik bilimsel e\u011fitim destekleri, hasta dernekleriyle y\u00fcr\u00fct\u00fclen i\u015f birlikleri ve kamuoyu bilgilendirme projeleriyle s\u00fcrece b\u00fct\u00fcnc\u00fcl katk\u0131 sunmay\u0131 hedefliyoruz. \u00c7\u00fcnk\u00fc nadir hastal\u0131klarda fark\u0131ndal\u0131k; erken tan\u0131 oran\u0131n\u0131 art\u0131ran, do\u011fru y\u00f6nlendirmeyi h\u0131zland\u0131ran ve tedaviye eri\u015fimi g\u00fc\u00e7lendiren en kritik e\u015fiklerden biridir.<\/p>\n\n\n\n<p>Abdi \u0130brahim olarak yakla\u015f\u0131m\u0131m\u0131z, bu alanda yaln\u0131zca \u00fcr\u00fcn sunan bir akt\u00f6r olmak de\u011fil; bilgi \u00fcretimine, i\u015f birliklerine ve s\u00fcrd\u00fcr\u00fclebilir \u00e7\u00f6z\u00fcmlere yat\u0131r\u0131m yapan uzun vadeli bir payda\u015f olmakt\u0131r. Toplumsal bilincin artmas\u0131, ancak t\u00fcm taraflar\u0131n ayn\u0131 hedef etraf\u0131nda, koordineli ve s\u00fcrekli bir \u00e7aba g\u00f6stermesiyle m\u00fcmk\u00fcn olabilir. Biz de bu ortak \u00e7aban\u0131n aktif bir par\u00e7as\u0131 olmaya devam ediyoruz.<\/p>\n\n\n\n<p><strong>Cevdet Cenk \u00c7etin, sizi ve Abdi \u0130brahim Nadir Hastal\u0131klar ekibini tan\u0131yabilir miyiz?<\/strong><\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignleft size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"695\" height=\"1024\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/cenk-cetin-copy1-695x1024.jpg\" alt=\"\" class=\"wp-image-4569\" style=\"width:179px;height:auto\" srcset=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/cenk-cetin-copy1-695x1024.jpg 695w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/cenk-cetin-copy1-204x300.jpg 204w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/cenk-cetin-copy1-768x1131.jpg 768w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/cenk-cetin-copy1-1043x1536.jpg 1043w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/cenk-cetin-copy1.jpg 1120w\" sizes=\"(max-width: 695px) 100vw, 695px\" \/><\/figure><\/div>\n\n\n<p>ODT\u00dc Biyoloji B\u00f6l\u00fcm\u00fc mezunuyum. 28 y\u0131l\u0131 a\u015fk\u0131n bir s\u00fcredir ila\u00e7 sekt\u00f6r\u00fcnde pazarlama ve sat\u0131\u015f alanlar\u0131nda liderlik rolleri \u00fcstlendim. Bug\u00fcn Abdi \u0130brahim\u2019de Nadir Hastal\u0131klar B\u00f6l\u00fcm Direkt\u00f6r\u00fc olarak g\u00f6rev yap\u0131yorum.<\/p>\n\n\n\n<p>Abdi \u0130brahim Nadir Hastal\u0131klar ekibi; medikal, pazarlama, pazar eri\u015fimi ve saha operasyonlar\u0131n\u0131 entegre \u015fekilde y\u00f6neten, y\u00fcksek uzmanl\u0131k seviyesine sahip bir yap\u0131dan olu\u015fuyor. Biz kendimizi yaln\u0131zca \u00fcr\u00fcn sunan bir ekip olarak konumland\u0131rm\u0131yoruz. Tan\u0131 s\u00fcrecinden tedaviye ve uzun d\u00f6nem takibe kadar uzanan hasta yolculu\u011funu b\u00fct\u00fcnc\u00fcl bi\u00e7imde ele alan, sa\u011fl\u0131k ekosisteminin t\u00fcm payda\u015flar\u0131yla yak\u0131n i\u015f birli\u011fi i\u00e7inde \u00e7al\u0131\u015fan bir model benimsiyoruz. Stratejik hedefimiz; nadir hastal\u0131klar alan\u0131nda T\u00fcrkiye\u2019de s\u00fcrd\u00fcr\u00fclebilir bir uzmanl\u0131k platformu olu\u015fturmak ve kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lara bilimsel temelli \u00e7\u00f6z\u00fcmler geli\u015ftirmektir.<\/p>\n\n\n\n<p><strong>D\u00fcnya genelinde ve T\u00fcrkiye\u2019de nadir hastal\u0131klar\u0131n g\u00fcncel tablosunu nas\u0131l de\u011ferlendiriyorsunuz?<\/strong><\/p>\n\n\n\n<p><strong>Cevdet Cenk \u00c7etin:<\/strong> Bug\u00fcn d\u00fcnya genelinde 7.000\u2019den fazla nadir hastal\u0131k tan\u0131mlanm\u0131\u015f durumda ve yakla\u015f\u0131k 300 milyon insan bu hastal\u0131klarla ya\u015f\u0131yor. Avrupa Birli\u011fi tan\u0131m\u0131na g\u00f6re bir hastal\u0131\u011f\u0131n nadir kabul edilebilmesi i\u00e7in 10.000 ki\u015fide 5\u2019ten az g\u00f6r\u00fclmesi gerekiyor. T\u00fcrkiye\u2019de hen\u00fcz kapsaml\u0131 bir ulusal kay\u0131t sistemi bulunmamakla birlikte, toplam hasta say\u0131s\u0131n\u0131n 5\u20137 milyon aras\u0131nda oldu\u011fu tahmin ediliyor. Nadir hastal\u0131klar\u0131n yakla\u015f\u0131k %70\u2019inin \u00e7ocukluk \u00e7a\u011f\u0131nda ba\u015flamas\u0131 ve b\u00fcy\u00fck \u00f6l\u00e7\u00fcde genetik temelli olmas\u0131, erken tan\u0131 ve genetik test altyap\u0131s\u0131n\u0131n kritik \u00f6nemini ortaya koyuyor.<\/p>\n\n\n\n<p>Son yirmi y\u0131lda tan\u0131 teknolojilerindeki ilerlemeler ve genetik-molek\u00fcler y\u00f6ntemlerin yayg\u0131nla\u015fmas\u0131, nadir hastal\u0131klar\u0131n daha erken ve do\u011fru \u015fekilde te\u015fhis edilmesini sa\u011flad\u0131. Bu geli\u015fmeler yaln\u0131zca tan\u0131 s\u00fcre\u00e7lerini h\u0131zland\u0131rmakla kalmad\u0131, ayn\u0131 zamanda tedaviye eri\u015fimi de daha m\u00fcmk\u00fcn ve s\u00fcrd\u00fcr\u00fclebilir hale getirdi.<\/p>\n\n\n\n<p>End\u00fcstri taraf\u0131nda artan Ar-Ge yat\u0131r\u0131mlar\u0131, yenilik\u00e7i tedavi se\u00e7eneklerinin geli\u015ftirilmesine zemin haz\u0131rlad\u0131. Nadir hastal\u0131klar bug\u00fcn, hasta odakl\u0131 yakla\u015f\u0131m\u0131n ve \u00e7ok payda\u015fl\u0131 i\u015f birliklerinin merkezinde yer alan stratejik bir sa\u011fl\u0131k alan\u0131 olarak konumlan\u0131yor. T\u00fcrkiye\u2019de ise sa\u011fl\u0131k otoriteleri, ila\u00e7 end\u00fcstrisi ve hasta dernekleri aras\u0131ndaki i\u015f birlikleri sayesinde fark\u0131ndal\u0131k \u00f6nemli \u00f6l\u00e7\u00fcde artt\u0131; bu da do\u011frudan hastalar\u0131n ve ailelerinin ya\u015fam kalitesine olumlu yans\u0131d\u0131.<\/p>\n\n\n\n<p><strong>Nadir hastal\u0131klarda tan\u0131 s\u00fcrecinin uzunlu\u011fu \u00f6nemli bir sorun. T\u00fcrkiye\u2019de erken tan\u0131 konusunda sizce en b\u00fcy\u00fck eksiklik nedir?<\/strong><\/p>\n\n\n\n<p><strong>Cevdet Cenk \u00c7etin:<\/strong> Nadir hastal\u0131klarla ya\u015fayan bireyler i\u00e7in s\u00fcre\u00e7 \u00e7o\u011fu zaman belirsizlikle ba\u015flar. Do\u011fru tan\u0131ya ula\u015fma s\u00fcreci, y\u0131llar s\u00fcrebilen hem hasta hem de ailesi i\u00e7in fiziksel ve duygusal a\u00e7\u0131dan olduk\u00e7a y\u0131prat\u0131c\u0131 bir deneyime d\u00f6n\u00fc\u015febiliyor. Literat\u00fcre g\u00f6re nadir hastal\u0131klarda tan\u0131ya ula\u015fma s\u00fcresi ortalama 5 ila 7 y\u0131l aras\u0131nda de\u011fi\u015fiyor. Hastalar\u0131n \u00f6nemli bir b\u00f6l\u00fcm\u00fc do\u011fru tan\u0131ya ula\u015fana kadar 3\u20135 farkl\u0131 hekim g\u00f6r\u00fcyor ve baz\u0131 vakalarda yanl\u0131\u015f tan\u0131 oran\u0131 %40\u2019lara kadar \u00e7\u0131kabiliyor. Tan\u0131 sonras\u0131nda ise tedaviye eri\u015fim, mevcut se\u00e7eneklerin s\u0131n\u0131rl\u0131l\u0131\u011f\u0131 nedeniyle yeni bir zorluk alan\u0131 olarak kar\u015f\u0131m\u0131za \u00e7\u0131k\u0131yor.<\/p>\n\n\n\n<p>Son on y\u0131lda tan\u0131 alan\u0131nda ya\u015fanan bilimsel ve teknolojik geli\u015fmeler sayesinde bu tablo giderek iyile\u015fmektedir. Geli\u015fmi\u015f tan\u0131 y\u00f6ntemleri, hastalar\u0131n tan\u0131 alma s\u00fcresini anlaml\u0131 \u00f6l\u00e7\u00fcde k\u0131saltm\u0131\u015f; erken te\u015fhis sayesinde tedaviye daha h\u0131zl\u0131 eri\u015fimin \u00f6n\u00fc a\u00e7\u0131lm\u0131\u015ft\u0131r. Bu noktada Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131\u2019n\u0131n yenido\u011fan tarama programlar\u0131na \u00f6ncelik vermesi ve evlilik \u00f6ncesi taramalar\u0131n yayg\u0131nla\u015ft\u0131r\u0131lmas\u0131, toplum sa\u011fl\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan son derece stratejik ve de\u011ferli ad\u0131mlard\u0131r.<\/p>\n\n\n\n<p>Bununla birlikte, fark\u0131ndal\u0131\u011f\u0131n t\u00fcm sa\u011fl\u0131k basamaklar\u0131nda daha da art\u0131r\u0131lmas\u0131, multidisipliner yakla\u015f\u0131m\u0131n g\u00fc\u00e7lendirilmesi ve tan\u0131 merkezlerinin yayg\u0131nla\u015ft\u0131r\u0131lmas\u0131 erken tan\u0131 s\u00fcrecinin daha da iyile\u015ftirilmesine katk\u0131 sa\u011flayacakt\u0131r.<\/p>\n\n\n\n<p><strong>\u015eirketinizin nadir hastal\u0131klar alan\u0131ndaki \u00fcr\u00fcn portf\u00f6y\u00fcnden s\u00f6z eder misiniz? \u00d6n\u00fcm\u00fczdeki d\u00f6nemde yeni \u00fcr\u00fcnler gelecek mi?<\/strong><\/p>\n\n\n\n<p><strong>Cevdet Cenk \u00c7etin:<\/strong> Abdi \u0130brahim olarak \u00f6zellikle genetik ve n\u00f6rolojik temelli nadir hastal\u0131klarda g\u00fc\u00e7l\u00fc bir portf\u00f6ye sahibiz. \u00d6rne\u011fin spinal m\u00fcsk\u00fcler atrofi (SMA), her 10.000 do\u011fumda yakla\u015f\u0131k 1 vakada g\u00f6r\u00fclen ve tedavi edilmedi\u011finde ciddi morbidite ve mortalite riski ta\u015f\u0131yan bir hastal\u0131k. T\u00fcrkiye\u2019de yenido\u011fan tarama program\u0131na al\u0131nmas\u0131, erken tan\u0131 a\u00e7\u0131s\u0131ndan \u00f6nemli bir e\u015fik oldu.<\/p>\n\n\n\n<p>Bu alanda sundu\u011fumuz yenilik\u00e7i tedavi se\u00e7enekleriyle hastalar\u0131n ya\u015fam s\u00fcresi ve fonksiyonel kapasitesinde anlaml\u0131 iyile\u015fmeler sa\u011flanabiliyor.<\/p>\n\n\n\n<p>Bunun yan\u0131 s\u0131ra n\u00f6rolojik ve metabolik temelli di\u011fer nadir hastal\u0131klarda da portf\u00f6y\u00fcm\u00fcz\u00fc geni\u015fletmeye y\u00f6nelik \u00e7al\u0131\u015fmalar y\u00fcr\u00fct\u00fcyoruz. Global i\u015f birlikleri ve stratejik ortakl\u0131klar arac\u0131l\u0131\u011f\u0131yla \u00f6n\u00fcm\u00fczdeki d\u00f6nemde yeni molek\u00fclleri T\u00fcrkiye\u2019de hastalarla bulu\u015fturmay\u0131 hedefliyoruz.<\/p>\n\n\n\n<p>Amac\u0131m\u0131z k\u0131sa vadeli de\u011fil; uzun soluklu ve s\u00fcrd\u00fcr\u00fclebilir bir nadir hastal\u0131klar platformu olu\u015fturmak.<\/p>\n\n\n\n<p><strong>Nadir hastal\u0131klarla ya\u015fayan bireylere ve ailelerine bu \u00f6zel g\u00fcnde vermek istedi\u011finiz mesaj nedir?<\/strong><\/p>\n\n\n\n<p><strong>Figen Bilgen:<\/strong> Nadir hastal\u0131klarla ya\u015fayan bireyler ve aileleri, son derece zorlu ve sab\u0131r gerektiren bir s\u00fcre\u00e7ten ge\u00e7iyor. Tan\u0131dan tedaviye uzanan bu yol, yaln\u0131zca t\u0131bbi de\u011fil; ayn\u0131 zamanda duygusal ve sosyal boyutlar\u0131 olan bir deneyim.<\/p>\n\n\n\n<p>Bu s\u00fcre\u00e7te hastalar\u0131m\u0131z\u0131n en iyi \u015fekilde tedaviye ula\u015fabilmesi ve tedavilerinin s\u00fcrd\u00fcr\u00fclebilirli\u011fi i\u00e7in kararl\u0131l\u0131kla \u00e7al\u0131\u015f\u0131yoruz. Hayat\u0131 iyile\u015ftirme sorumlulu\u011fumuzla, her bir hastan\u0131n ya\u015fam\u0131ndaki olumlu de\u011fi\u015fimin bir par\u00e7as\u0131 olmay\u0131 \u00f6nemsiyoruz.<\/p>\n\n\n\n<p>28 \u015eubat, bu ortak m\u00fccadeleyi g\u00f6r\u00fcn\u00fcr k\u0131lan \u00f6zel bir g\u00fcn. Ancak bizim i\u00e7in nadir hastal\u0131klar alan\u0131ndaki sorumluluk, y\u0131l\u0131n her g\u00fcn\u00fc devam eden uzun soluklu bir \u00e7al\u0131\u015fma alan\u0131d\u0131r.<\/p>\n\n\n\n<p><strong>Cevdet Cenk \u00c7etin:<\/strong> Bilim nadir hastal\u0131klar alan\u0131nda \u00f6nemli bir ivme yakalad\u0131. Son 10 y\u0131lda onaylanan tedavi say\u0131s\u0131n\u0131n \u00f6nceki 30 y\u0131l\u0131n toplam\u0131n\u0131 a\u015fmas\u0131, bu alandaki ilerlemenin en somut ve umut verici g\u00f6stergelerinden biri. Nadir hastal\u0131klarla ya\u015fayan t\u00fcm bireylerin ve ailelerinin, yaln\u0131zca bug\u00fcn de\u011fil her g\u00fcn yanlar\u0131nda oldu\u011fumuzu bilmelerini isterim. Her bireyin sa\u011fl\u0131kl\u0131 bir ya\u015fam s\u00fcrme hakk\u0131 oldu\u011funa inan\u0131yor; bu inan\u00e7la bilimin rehberli\u011finde var g\u00fcc\u00fcm\u00fczle \u00e7al\u0131\u015f\u0131yoruz.<\/p>\n\n\n\n<p>Att\u0131\u011f\u0131m\u0131z her ad\u0131m\u0131n bir aile i\u00e7in umut, ula\u015ft\u0131rd\u0131\u011f\u0131m\u0131z her tedavinin ise bir insan\u0131n gelece\u011fi oldu\u011funu bilerek yol al\u0131yoruz. \u201cNadir\u201d olan\u0131n yaln\u0131z olmad\u0131\u011f\u0131n\u0131 hat\u0131rlatmaya, bu alanda sorumluluk almaya ve \u201cnadir\u201din sesi olmaya devam edece\u011fiz.<\/p>\n\n\n\n<p>\u00c7\u00fcnk\u00fc nadir olmak, yaln\u0131z olmak de\u011fildir.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-2-web-2-1024x683.jpg\" alt=\"\" class=\"wp-image-4586\" style=\"width:479px;height:auto\" srcset=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-2-web-2-1024x683.jpg 1024w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-2-web-2-300x200.jpg 300w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-2-web-2-768x512.jpg 768w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-2-web-2-1536x1024.jpg 1536w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/02\/toplu-2-web-2-2048x1366.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/div>","protected":false},"excerpt":{"rendered":"<p>T\u00fcrk ila\u00e7 sekt\u00f6r\u00fcn\u00fcn lider \u015firketi Abdi \u0130brahim, nadir hastal\u0131klar alan\u0131n\u0131 yaln\u0131zca bir terap\u00f6tik ba\u015fl\u0131k olarak de\u011fil, uzun soluklu bir sorumluluk alan\u0131 olarak konumland\u0131r\u0131yor. Bilimsel ilerlemelerin h\u0131z kazand\u0131\u011f\u0131, erken tan\u0131 ve yenilik\u00e7i tedavi se\u00e7eneklerinin giderek daha fazla \u00f6nem kazand\u0131\u011f\u0131 bu alanda \u015firket; hasta odakl\u0131 yakla\u015f\u0131m\u0131, g\u00fc\u00e7l\u00fc Ar-Ge altyap\u0131s\u0131 ve uluslararas\u0131 i\u015f birlikleriyle s\u00fcrd\u00fcr\u00fclebilir bir de\u011fer yaratmay\u0131 hedefliyor. Re\u00e7eteli \u00dcr\u00fcnler Pazarlama ve Sat\u0131\u015f Grup Ba\u015fkan\u0131 Figen Bilgen ile Nadir Hastal\u0131klar B\u00f6l\u00fcm Direkt\u00f6r\u00fc Cevdet Cenk \u00c7etin, nadir hastal\u0131klarda eri\u015fimden fark\u0131ndal\u0131\u011fa, tan\u0131 s\u00fcre\u00e7lerinden gelecek vizyonuna uzanan kapsaml\u0131 bir perspektifi payla\u015f\u0131yor.<\/p>\n","protected":false},"author":1,"featured_media":4567,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,3],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4589"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4589"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4589\/revisions"}],"predecessor-version":[{"id":4590,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4589\/revisions\/4590"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4567"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}